my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Ben-Gurion University of the Negev’s Prof. Ilana Nathan and her team are interested in cell death. Specifically, they investigate all sorts of chemical compounds that can kill leukemia cancer cells by taking a ‘WISE’ investigational approach. What’s unique about the research is that she and her team more
Hybrigenics announced the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL). World-wide, about 130,000 new patients are diagnosed each year with CLL, for which there is currently no definitive cure. CLL is designated as an orphan disease in th more
NOXXON Pharma announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer®. CXCL12 signaling has been shown to play an important ro more
Amplicon sequencing with the Genome Sequencer FLX System has already enabled a wide variety of scientific discoveries, particularly in clinical research. The introduction of the GS FLX Titanium Chemistry and the release of the associated amplicon sequencing protocols will continue to expand applications, as more and longer amplicons increase the depth of analysis for detecting rare variants and improve coverage of gene loci more
RNA silencing is a mechanism of gene regulation whereby small double-stranded RNAs (dsRNAs) of 21-18 nucleotides in length cause mRNA degradation, mRNA translation, or chromatin modification. In the past years, more than 500 novel genes have been identified in animals and plants encoding small transcripts that can form small dsRNA hairpin structures. From these hairpin precursors, small 22-nt RNAs - so called microRNAs (miRNA) - are excised by dsRNA-specific endonucleases. The miRNAs are then integrated in ribonucleoprotein particles (RNPs). Most miRNAs in animals act by binding to partially complementary regions of the 3' untranslated region of their target mRNA, thereby blocking translation. more
Next-generation sequencing techniques have emerged as powerful tools for the understanding of cancer genomes. In recent years, whole-exome and whole-genome sequencing strategies have enabled the annotation of a comprehensive mutation landscape of chronic lymphocytic leukemia (CLL), the most frequen more
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Europe and North America. For many years scientists and doctors have been working on introducing the most effective therapy into CLL as prognosis of survival time and the course of the disease differ among patients, which might pose a more
Abstract Background: Deletion 13q14.3 is the most common cytogenetic abnormality in chronic lymphocytic leukemia (CLL). Previously it was reported that miR‐15/16 is the target of 13q14 deletions and plays a tumor suppressor role by suppressing Bcl‐2. Therefore, Bcl‐2 expression was examined mo more
Introduction Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates more
Introduction Global Markets Direct’s, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Le more
Introduction Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2012', provides an overview of the Chronic Lymphocytic Leukemia (CLL) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), comple more
Overview Business Strategy Management Team Board Of Directors Scientific Advisory Board Clinical Advisory Board From Heparin to Glycodrugs Endotis Pharma Drug Discovery Engine Targeted Diseases R&D Programs Targeted Diseases 1.1 Thrombosis The thrombosis market represents an estimated 45 million pat more
Corporate Overview History Management Team Board of Directors Collaborators & Advisors Current Investors Overview Therapeutic Areas Pipeline Publications Press Releases Presentations Careers Pipeline CD200 fusion protein (CD200Fc) CD200 is a transmembrane protein broadly expressed on a variety of ce more
Home | Contact Us | Sitemap Portfolio Strategy Pipeline RECOTHROM® IL-21 PEG-Interferon lambda IL-31 mAb Out-licensed PEG-Interferon lambda (PEG-IFN-λ, PEG-IL-29) PEG-IFN lambda is a unique, novel Interferon with the potential to become the new treatment of choice for patients with Hepatitis C PEG-I more
Chronic lymphocytic leukemia Chronic lymphocytic leukemia (also known as "chronic lymphoid leukemia" or "CLL"), is a type of leukemia , or cancer of the white blood cells (lymphocytes ). CLL affects a particular lymphocyte, the B cell , which or ... more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
